Edition:
India

Onconova Therapeutics Inc (ONTX.OQ)

ONTX.OQ on NASDAQ Stock Exchange Capital Market

2.33USD
18 Jul 2019
Change (% chg)

-- (--)
Prev Close
$2.33
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
12,561
52-wk High
$11.17
52-wk Low
$1.71

Latest Key Developments (Source: Significant Developments)

Onconova Therapeutics, Inc. Reports Business Highlights And First Quarter 2019 Financial Results
Tuesday, 14 May 2019 

May 14 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS, INC. REPORTS BUSINESS HIGHLIGHTS AND FIRST QUARTER 2019 FINANCIAL RESULTS.ONCONOVA THERAPEUTICS INC QUARTERLY LOSS PER SHARE $1.29.ONCONOVA THERAPEUTICS INC - CDK 4/6 INHIBITOR IS EXPECTED TO ENTER A PHASE 1 CLINICAL TRIAL IN U.S. DURING SECOND HALF OF 2019..ONCONOVA THERAPEUTICS INC - CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2019, TOTALED $10.4 MILLION COMPARED TO $17.0 MILLION AT DECEMBER 31, 2018..  Full Article

Onconova Therapeutics Announces License Agreement With Hanx Biopharmaceuticals
Monday, 13 May 2019 

May 13 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH HANX BIOPHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE RIGOSERTIB IN GREATER CHINA.ONCONOVA THERAPEUTICS INC - ONCONOVA TO RECEIVE $4 MILLION UPFRONT.ONCONOVA THERAPEUTICS - HANX TO DEDICATE $2 MILLION IN LOCAL CURRENCY TO INVEST IN GREATER CHINA RIGOSERTIB CLINICAL DEVELOPMENT OVER NEXT 24 MONTHS.ONCONOVA THERAPEUTICS INC - MAY ALSO RECEIVE UP TO $45.5 MILLION FROM DEAL.ONCONOVA THERAPEUTICS INC - DEAL INCLUDES $2 MILLION FEE AND $2 MILLION FOR ONCONOVA SHARES PURCHASED AT A PREMIUM.ONCONOVA THERAPEUTICS INC - GRANTED TO HANX EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE RIGOSERTIB IN GREATER CHINA.ONCONOVA THERAPEUTICS INC - GRANTED TO HANX NON-EXCLUSIVE LICENSE TO MANUFACTURE RIGOSERTIB IN GREATER CHINA.ONCONOVA THERAPEUTICS INC - ONCONOVA WILL INITIALLY SUPPLY FINISHED PRODUCT FOR SALE IN LICENSED TERRITORIES..ONCONOVA THERAPEUTICS INC - HANX WILL ALSO SUPPORT ONCONOVA'S CLINICAL TRIAL INITIATIVES IN THE TERRITORY.  Full Article

Onconova Submits Special Protocol Assessment To FDA For Phase 3 Trial Of Oral Rigosertib In Combination With Azacitidine
Wednesday, 2 Jan 2019 

Jan 2 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA SUBMITS SPECIAL PROTOCOL ASSESSMENT (SPA) TO FDA FOR PHASE 3 TRIAL OF ORAL RIGOSERTIB IN COMBINATION WITH AZACITIDINE (VIDAZA®) FOR FIRST-LINE MYELODYSPLASTIC SYNDROMES (MDS).ONCONOVA THERAPEUTICS INC - 2019 FOCUS REMAINS ON COMPLETION OF PIVOTAL INSPIRE TRIAL STUDYING INTRAVENOUS RIGOSERTIB IN SECOND-LINE HIGHER-RISK MDS.ONCONOVA THERAPEUTICS INC - COMPANY EXPECTS ITS DIALOGUE WITH FDA ON THE SPA SUBMISSION TO CONCLUDE IN H1 2019.ONCONOVA THERAPEUTICS INC - SPA SUBMITTED TO FDA BEFORE YEAR-END 2018.  Full Article

Onconova Therapeutics Highlights Results From Phase 2 Trial Of Oral Rigosertib
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA HIGHLIGHTS RESULTS FROM PHASE 2 TRIAL OF ORAL RIGOSERTIB IN COMBINATION WITH AZACITIDINE (VIDAZA®) IN MYELODYSPLASTIC SYNDROMES (MDS) AT THE 2018 ASH ANNUAL MEETING.ONCONOVA THERAPEUTICS INC - PIVOTAL PHASE 3 TRIAL IS PLANNED IN AN HMA AND CHEMOTHERAPY NAÏVE HIGHER RISK - MDS PATIENT POPULATION.ONCONOVA THERAPEUTICS INC - ORR OF 90% REPORTED IN PHASE 2 STUDY IN HYPOMETHYLATING AGENT NAÏVE PATIENTS, INCLUDING CR RATE OF 34%.ONCONOVA THERAPEUTICS INC - ORR OF 54% AND CR/PARTIAL RESPONSE OF 8% IN HMA FAILED PATIENTS REPORTED.ONCONOVA THERAPEUTICS INC - ORAL RIGOSERTIB IN COMBINATION WITH AZACITIDINE WAS WELL TOLERATED IN HMA NAÏVE AND HMA FAILED HR-MDS PATIENTS.  Full Article

Onconova Therapeutics Reports Q1 Loss Per Share Of $0.34
Tuesday, 15 May 2018 

May 15 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS, INC. REPORTS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR FIRST QUARTER 2018.ONCONOVA THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.34.  Full Article

Onconova Therapeutics Says Offering Up To 18.5 Mln Units Of Common Stock, Warrants
Wednesday, 18 Apr 2018 

April 17 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS - OFFERING UP TO 18.5 MILLION UNITS (UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT).  Full Article

Onconova Says Moving Forward With Pivotal Late-Stage Trial
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA MOVING FORWARD WITH PHASE 3 INSPIRE PIVOTAL TRIAL WITH INCREASED SAMPLE SIZE FOLLOWING PROMISING INTERIM ANALYSIS.ONCONOVA - DMC RECOMMENDS CONTINUATION OF INSPIRE TRIAL WITH TRIAL EXPANSION PER ADAPTIVE DESIGN BASED ON INTERIM ANALYSIS RESULTS FOR OS.ONCONOVA - TRIAL EXECUTIVE COMMITTEE UNANIMOUSLY AGREED TO CONTINUE INTENT TO TREAT STUDY POPULATION, INCREASE CLINICAL TRIAL ENROLLMENT.ONCONOVA - EXPANDED INSPIRE STUDY WILL INCREASE ENROLLMENT BY ADDING 135 PATIENTS TO ORIGINAL TARGET, TO REACH TOTAL ENROLLMENT OF 360 PATIENTS.  Full Article

Onconova Therapeutics Says Entered Into Cooperative Research And Development Agreement With NCI
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS SAYS ENTERED INTO COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH NATIONAL CANCER INSTITUTE.ONCONOVA THERAPEUTICS - UNDER TERMS, NCI WILL CONDUCT RESEARCH ON RIGOSERTIB IN PEDIATRIC CANCER ASSOCIATED RASOPATHIES.  Full Article

Onconova Therapeutics Announces License And Collaborative Development Agreement With Hanx Biopharma
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AND COLLABORATIVE DEVELOPMENT AGREEMENT WITH HANX BIOPHARMACEUTICALS FOR ON 123300, A DUAL INHIBITOR OF CDK4/6 + ARK5.ONCONOVA THERAPEUTICS INC - HANX WILL FUND STUDIES TOWARDS INVESTIGATIONAL NEW DRUG APPLICATIONS IN BOTH U.S. AND CHINA.ONCONOVA THERAPEUTICS INC - AGREEMENT INCLUDES LICENSING FEE, CUSTOMARY MILESTONE PAYMENTS AND ROYALTIES ON SALES OF ON 123300.ONCONOVA THERAPEUTICS INC - HANX TO COMMERCIALIZE ON 123300 IN GREATER CHINA, ONCONOVA RETAINS RIGHTS IN REST OF WORLD.  Full Article

Onconova Therapeutics files for mixed shelf offering of upto $84.5 mln
Tuesday, 21 Nov 2017 

Nov 20 (Reuters) - Onconova Therapeutics Inc ::Onconova Therapeutics Inc files for mixed shelf offering of upto $84.5 million- SEC filing‍​.  Full Article